The role of early biologic therapy in inflammatory bowel disease

Research output: Contribution to journalReview articlepeer-review

95 Scopus citations


The goals for treatment of inflammatory bowel diseases (IBDs) are changing from elimination of symptoms toward complete disease control-a process that demands both clinical and endoscopic remission. This new IBD treatment paradigm has been shifting from a conventional "step-up" approach toward a more "top-down" early intervention treatment strategy. Recent studies suggest that the use of biologic agents, specifically those targeting tumor necrosis factor alpha, earlier in the treatment course improves patient outcomes and can prevent progression to irreversible bowel damage. Although the strategy of early intervention has accumulating evidence in Crohn's disease, there is less evidence supporting its impact in ulcerative colitis.

Original languageEnglish
Pages (from-to)1896-1905
Number of pages10
JournalInflammatory Bowel Diseases
Issue number12
StatePublished - 1 Dec 2019


  • Crohn's disease
  • Early biologic therapy
  • Inflammatory bowel disease
  • Top-down therapy
  • Ulcerative colitis


Dive into the research topics of 'The role of early biologic therapy in inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this